The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

Ritonavir is the most potent cytochrome P450 (CYP) 3A4 inhibitor in clinical use and is often applied as a booster for drugs with low oral bioavailability due to CYP3A4-mediated biotransformation, as in the treatment of HIV (e.g., lopinavir/ritonavir) and more recently COVID-19 (Paxlovid or nirmatre...

Descripción completa

Detalles Bibliográficos
Autores principales: Loos, Nancy H. C., Beijnen, Jos H., Schinkel, Alfred H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456214/
https://www.ncbi.nlm.nih.gov/pubmed/36077262
http://dx.doi.org/10.3390/ijms23179866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456214/
https://www.ncbi.nlm.nih.gov/pubmed/36077262
http://dx.doi.org/10.3390/ijms23179866

Ejemplares similares